240 related articles for article (PubMed ID: 32897878)
21. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
[TBL] [Abstract][Full Text] [Related]
22. Pre-existing immunity does not impair the engraftment of CRISPR-Cas9-edited cells in rhesus macaques conditioned with busulfan or radiation.
Essawi K; Hakami W; Naeem Khan MB; Martin R; Zeng J; Chu R; Uchida N; Bonifacino AC; Krouse AE; Linde NS; Donahue RE; Blobel GA; Gerdemann U; Kean LS; Maitland SA; Wolfe SA; Metais JY; Gottschalk S; Bauer DE; Tisdale JF; Demirci S
Mol Ther Methods Clin Dev; 2023 Jun; 29():483-493. PubMed ID: 37273902
[TBL] [Abstract][Full Text] [Related]
23. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β
Fu B; Liao J; Chen S; Li W; Wang Q; Hu J; Yang F; Hsiao S; Jiang Y; Wang L; Chen F; Zhang Y; Wang X; Li D; Liu M; Wu Y
Nat Med; 2022 Aug; 28(8):1573-1580. PubMed ID: 35922667
[TBL] [Abstract][Full Text] [Related]
24. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells.
DeWitt MA; Magis W; Bray NL; Wang T; Berman JR; Urbinati F; Heo SJ; Mitros T; Muñoz DP; Boffelli D; Kohn DB; Walters MC; Carroll D; Martin DI; Corn JE
Sci Transl Med; 2016 Oct; 8(360):360ra134. PubMed ID: 27733558
[TBL] [Abstract][Full Text] [Related]
25. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
27. Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H; Locatelli F; Sharma A; Bhatia M; Mapara M; Molinari L; Wall D; Liem RI; Telfer P; Shah AJ; Cavazzana M; Corbacioglu S; Rondelli D; Meisel R; Dedeken L; Lobitz S; de Montalembert M; Steinberg MH; Walters MC; Eckrich MJ; Imren S; Bower L; Simard C; Zhou W; Xuan F; Morrow PK; Hobbs WE; Grupp SA;
N Engl J Med; 2024 May; 390(18):1649-1662. PubMed ID: 38661449
[TBL] [Abstract][Full Text] [Related]
28. The CCR5 Gene Edited CD34
Karuppusamy KV; Demosthenes JP; Venkatesan V; Christopher AC; Babu P; Azhagiri MK; Jacob A; Ramalingam VV; Rangaraj S; Murugesan MK; Marepally SK; Varghese GM; Srivastava A; Kannangai R; Thangavel S
Front Immunol; 2022; 13():792684. PubMed ID: 35359982
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic adenine base editing of human hematopoietic stem cells.
Liao J; Chen S; Hsiao S; Jiang Y; Yang Y; Zhang Y; Wang X; Lai Y; Bauer DE; Wu Y
Nat Commun; 2023 Jan; 14(1):207. PubMed ID: 36639729
[TBL] [Abstract][Full Text] [Related]
30. Induction of therapeutic levels of HbF in genome-edited primary β
Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
[TBL] [Abstract][Full Text] [Related]
31. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS
Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363
[TBL] [Abstract][Full Text] [Related]
32. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
33. Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies.
Ureña-Bailén G; Block M; Grandi T; Aivazidou F; Quednau J; Krenz D; Daniel-Moreno A; Lamsfus-Calle A; Epting T; Handgretinger R; Wild S; Mezger M
CRISPR J; 2023 Feb; 6(1):5-16. PubMed ID: 36662546
[TBL] [Abstract][Full Text] [Related]
34. A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates.
Radtke S; Adair JE; Giese MA; Chan YY; Norgaard ZK; Enstrom M; Haworth KG; Schefter LE; Kiem HP
Sci Transl Med; 2017 Nov; 9(414):. PubMed ID: 29093179
[TBL] [Abstract][Full Text] [Related]
35. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
[TBL] [Abstract][Full Text] [Related]
36. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
37. Restoring T and B cell generation in X-linked severe combined immunodeficiency mice through hematopoietic stem cells adenine base editing.
Zhang L; Li K; Liu Z; An L; Wei H; Pang S; Cao Z; Huang X; Jin X; Ma X
Mol Ther; 2024 Jun; 32(6):1658-1671. PubMed ID: 38532630
[TBL] [Abstract][Full Text] [Related]
38. Multiplex CRISPR/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations.
Samuelson C; Radtke S; Zhu H; Llewellyn M; Fields E; Cook S; Huang MW; Jerome KR; Kiem HP; Humbert O
Mol Ther Methods Clin Dev; 2021 Dec; 23():507-523. PubMed ID: 34853798
[TBL] [Abstract][Full Text] [Related]
39. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
[TBL] [Abstract][Full Text] [Related]
40. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
